Profile

HDAX Therapeutics, a biotechnology company pioneering a novel approach to target HDAC6 to address critical unmet medical needs in renal, cardiometabolic and select neurological diseases, starting with ADPKD. Its innovative 2-site binding mechanism has the potential to deliver best-in-class HDAC6-targeting therapeutics and tackles major limitations of first generation compounds. HDAX closed an oversubscribed $4M seed financing round in Q4 2024 to nominate a development candidate and advance its pipeline programs.

HDAX Therapeutics logo

Website

hdaxtx.com

Contact


Event details

Date: November 3 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

22 in total